Yang et al., Aviscumine (ME-503) suppresses the growth of melanoma by potentially targeting c-Myc pathway, Cancer Res 79 (13 Suppl): 1861 (2019)

U. Trefzer et al., Aviscumine (ME-503) – Skin Reaction as significant Factor for its Efficacy – Expanded Evaluation of the Results from the Phase II Trial NCT00658437 in Patients with Unresectable stage IV Metastatic Melanoma, Immunother Open Acc 3: 135-139 (2017)

S. Schötterl et al., Viscumins functionally modulate cell motility-associated gene expression, Int. J. Oncology 50: 684-696 (2017)

P. Mohr et al., Aviscumine (ME-503), a plant protein with a novel mode of action, shows clinical activity in unresectable stage IV metastatic melanoma: data from a phase II trial, Cancer Res 76 (14 Suppl): Abstract nr CT123 (2016)

U. Trefzer et al., Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study, Journal for Immunotherapy of Cancer 2: 27 (2014)

H. Zwierzina et al., The preclinical and clinical activity of aviscumine: A potential anticancer drug, European Journal of Cancer 47: 1450-1457 (2011).

L. Bergmann et al., Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001), European Journal of Cancer 44: 1657-1662 (2008).

Müthing et al., Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acα2-6Galβ1-4GlcNAc residues are receptors for the anticancer drug rViscumin, FASEB J. 19: 103-105 (2005)

P. Schöffski et al., Weekly 24h infusion of aviscumine (rViscumin): A phase I study in patients with solid tumours, European Journal of Cancer 41: 1431-1438 (2005).

P. Schöffski et al., Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: A study of the European Organization for Research and Treatment of Cancer New Drug Development Group, Annals of Oncology 15: 1816-1824 (2004).

Müthing et al., Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally α2-6-sialylated neolacto-series gangliosides, Glycobiology 12: 485–497 (2002)